Pathology: la/mBC - HR-positive - 2nd line (L2);
| la/mBC - HR-positive - 2nd line (L2) | |||||||
| MONARCH 2, 2020 | DAWNA-1, 2021 | PALOMA-3, 2016 | FLIPPER, 2021 | MONALEESA-7, 2018 | MONALEESA-3, 2018 | ||
| palbociclib plus fulvestrant | 2 | T1 | T1 | ||||
| dalpiciclib plus fulvestrant | 1 | T1 | |||||
| abemaciclib plus fulvestrant | 1 | T1 | |||||
| ribociclib plus endocrine therapy | 1 | T1 | |||||
| ribociclib plus fulvestrant | 1 | T1 | |||||
| fulvestrant | 0 | T0 | T0 | T0 | T0 | T0 | |
| endocrine therapy | 0 | T0 | |||||